Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Canaccord Genuity – Smarter Analyst

Posted: April 1, 2020 at 9:47 am

Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on Crispr Therapeutics AG (CRSP) today and set a price target of $80.00. The companys shares closed last Tuesday at $42.41.

According to, Lee is a 3-star analyst with an average return of 0.1% and a 43.0% success rate. Lee covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Karyopharm Therapeutics.

Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $71.68, representing a 62.2% upside. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $80.00 price target.

See todays analyst top recommended stocks >>

Based on Crispr Therapeutics AGs latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $77.02 million and net profit of $30.54 million. In comparison, last year the company earned revenue of $115K and had a GAAP net loss of $47.59 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Read the rest here:
Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Canaccord Genuity - Smarter Analyst

Related Post

Comments are closed.